US approval of using 'wigofi' medicine to treat a liver disease

The famous weight loss medicine “Wigofo” produced by Novo Nordisk A/S obtained the approval of the US Food and Drug Administration to treat a dangerous form of liver disease, before his competitor, produced by Eli Lilly & Co. The injection has been approved to treat the disease known as mash or lipopteritis with metabolic syndrome, in adults with mediums to advanced liver, according to the leaves. This condition affects about 6% of adults in the United States, or about 14.9 million people, according to a statement released by the Food and Drug Administration on Friday. The drug is used with a low -calorie diet and an increased physical activity. This approval gives Novo Nordisk A/S the prestige of the prestigious GLP-1 drug market, which was widely known for weight loss. Additional uses, such as the treatment of liver disease, would expand its market share at a time when the company faces intense competition from the cheapest counter -workers and the company “Lily” according to “Bloomberg”. Novo’s US deposit receipts increased by 6% in the after -finished trade. On the other hand, the shares of Madrigal Pharmaceuticals Inc, which developed treatments for the same case, fell by 6.5%. Mash develops when fat accumulates in the liver, which causes infections and can eventually lead to more severe conditions such as cirrhosis or liver cancer. A significant improvement and a study showed that the “wigofi” medicine had captured the liver at 37% of patients, without increasing infections, compared to a 22% improvement in patients who obtained a false treatment. Placebo is a substance or medicine that contains no effective ingredient and which is used in medical studies as a comparison, as some patients may have a psychologist or physical improvement just because they believe they receive an actual treatment, known as the effect of the plasibo, and thus researchers can distinguish between the actual effect of the new cure and any improvement due to psychological or natural factors. Almost twice the number of patients who took the medicine was an improvement in liver infections compared to the group that took place for imaginary therapy, according to the company’s statement. Martin Holst Lang, the scientific president of Novo, said in the statement that a person out of every 3 is suffering from weight gain or obesity, has this condition. He added that “Wigofi” was not limited to stopping the activity of the disease in these patients, but also helped reflect the damage to the liver.